Tiotropium 18 mcg
Sponsors
Boehringer Ingelheim, GlaxoSmithKline, Neutec Ar-Ge San ve Tic A.Ş
Conditions
COPDExercisePulmonary Disease, Chronic Obstructive
Phase 3
A Randomized, Double-Blind, 4-way Crossover Study to Evaluate the Efficacy of of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
CompletedNCT01040728
Start: 2010-01-31Updated: 2014-06-30
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease
CompletedNCT01040689
Start: 2010-01-31Updated: 2014-06-30
Comparison of Tiotropium in the HandiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
CompletedNCT01126437
Start: 2010-05-31End: 2013-05-31Updated: 2014-06-20
The Purpose of This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotriopium 18 mcg Once Daily Over a 24-week Treatment Period in Subjects With COPD
CompletedNCT01777334
Start: 2013-01-23End: 2013-09-24Updated: 2018-01-24
The Purpose of the This Study is to Evaluate the Spirometric Effect (Trough FEV1) of Umeclidinium/Vilanterol 62.5/25 mcg Once Daily Compared With Tiotropium 18mcg Once Daily Over a a 12-week Treatment Period in Subjects With COPD Who Continue to Have Symptoms on Tiotropium
CompletedNCT01899742
Start: 2014-09-15End: 2015-07-22Updated: 2018-01-24
Phase 4
Tiotropium In Exercise
CompletedNCT00525512
Start: 2007-08-31Updated: 2013-12-24
Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD
CompletedNCT02541006
Start: 2014-11-30End: 2015-08-31Updated: 2020-06-16